tetano
Editor, Senior Moderator
JCI Insight
. 2022 Feb 22;e157031.
doi: 10.1172/jci.insight.157031. Online ahead of print.
Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
Ane Ogbe[SUP] 1 [/SUP], Matthew Pace[SUP] 1 [/SUP], Mustapha Bittaye[SUP] 2 [/SUP], Timothy Tipoe[SUP] 1 [/SUP], Sandra Adele[SUP] 1 [/SUP], Jasmini Alagaratnam[SUP] 3 [/SUP], Parvinder K Aley[SUP] 4 [/SUP], M Azim Ansari[SUP] 1 [/SUP], Anna Bara[SUP] 5 [/SUP], Samantha Broadhead[SUP] 6 [/SUP], Anthony Brown[SUP] 1 [/SUP], Helen Brown[SUP] 1 [/SUP], Federica Cappuccini[SUP] 2 [/SUP], Paola Cinardo[SUP] 7 [/SUP], Wanwisa Dejnirattisai[SUP] 8 [/SUP], Katie Ewer[SUP] 2 [/SUP], Henry Fok[SUP] 7 [/SUP], Pedro M Folegatti[SUP] 2 [/SUP], Jamie Fowler[SUP] 2 [/SUP], Leila Godfrey[SUP] 2 [/SUP], Anna L Goodman[SUP] 7 [/SUP], Bethany Jackson[SUP] 7 [/SUP], Daniel Jenkin[SUP] 2 [/SUP], Mathew Jones[SUP] 1 [/SUP], Stephanie Longet[SUP] 8 [/SUP], Rebecca A Makinson[SUP] 2 [/SUP], Natalie G Marchevsky[SUP] 4 [/SUP], Moncy Mathew[SUP] 7 [/SUP], Andrea Mazzella[SUP] 7 [/SUP], Yama F Mujadidi[SUP] 4 [/SUP], Lucia Parolini[SUP] 1 [/SUP], Claire Petersen[SUP] 9 [/SUP], Emma Plested[SUP] 4 [/SUP], Katrina Pollock[SUP] 5 [/SUP], Thurkka Rajeswaran[SUP] 7 [/SUP], Maheshi N Ramasamy[SUP] 4 [/SUP], Sarah Rhead[SUP] 4 [/SUP], Hannah Robinson[SUP] 4 [/SUP], Nicola Robinson[SUP] 1 [/SUP], Helen Sanders[SUP] 2 [/SUP], Sonia Serrano Fandos[SUP] 6 [/SUP], Tom Tipton[SUP] 8 [/SUP], Anele Waters[SUP] 7 [/SUP], Panagiota Zacharopoulou[SUP] 1 [/SUP], Eleanor Barnes[SUP] 1 [/SUP], Susanna Dunachie[SUP] 1 [/SUP], Philip Goulder[SUP] 1 [/SUP], Paul Klenerman[SUP] 1 [/SUP], Gavin R Screaton[SUP] 8 [/SUP], Alan Winston[SUP] 3 [/SUP], Adrian Vs Hill[SUP] 2 [/SUP], Sarah C Gilbert[SUP] 2 [/SUP], Miles Carroll[SUP] 8 [/SUP], Andrew J Pollard[SUP] 4 [/SUP], Sarah Fidler[SUP] 3 [/SUP], Julie Fox[SUP] 6 [/SUP], Teresa Lambe[SUP] 2 [/SUP], John Frater[SUP] 1 [/SUP]
Affiliations
Abstract
Duration of protection from SARS-CoV-2 infection in people with HIV (PWH) following vaccination is unclear. In a sub-study of the phase 2/3 the COV002 trial (NCT04400838), 54 HIV positive male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells >350 cells/ul) received two doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and MesoScale Discovery (MSD)), neutralisation, ACE-2 inhibition, gamma interferon ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that 6 months after vaccination the majority of measurable immune responses were greater than pre-vaccination baseline, but with evidence of a decline in both humoral and cell mediated immunity. There was, however, no significant difference compared to a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although were lower than wild type. Pre-existing cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater post-vaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the on-going policy to vaccinate PWH against SARS-CoV-2, and underpin the need for long-term monitoring of responses after vaccination.
Keywords: AIDS/HIV; Adaptive immunity; COVID-19; Cellular immune response; T cells.
. 2022 Feb 22;e157031.
doi: 10.1172/jci.insight.157031. Online ahead of print.
Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
Ane Ogbe[SUP] 1 [/SUP], Matthew Pace[SUP] 1 [/SUP], Mustapha Bittaye[SUP] 2 [/SUP], Timothy Tipoe[SUP] 1 [/SUP], Sandra Adele[SUP] 1 [/SUP], Jasmini Alagaratnam[SUP] 3 [/SUP], Parvinder K Aley[SUP] 4 [/SUP], M Azim Ansari[SUP] 1 [/SUP], Anna Bara[SUP] 5 [/SUP], Samantha Broadhead[SUP] 6 [/SUP], Anthony Brown[SUP] 1 [/SUP], Helen Brown[SUP] 1 [/SUP], Federica Cappuccini[SUP] 2 [/SUP], Paola Cinardo[SUP] 7 [/SUP], Wanwisa Dejnirattisai[SUP] 8 [/SUP], Katie Ewer[SUP] 2 [/SUP], Henry Fok[SUP] 7 [/SUP], Pedro M Folegatti[SUP] 2 [/SUP], Jamie Fowler[SUP] 2 [/SUP], Leila Godfrey[SUP] 2 [/SUP], Anna L Goodman[SUP] 7 [/SUP], Bethany Jackson[SUP] 7 [/SUP], Daniel Jenkin[SUP] 2 [/SUP], Mathew Jones[SUP] 1 [/SUP], Stephanie Longet[SUP] 8 [/SUP], Rebecca A Makinson[SUP] 2 [/SUP], Natalie G Marchevsky[SUP] 4 [/SUP], Moncy Mathew[SUP] 7 [/SUP], Andrea Mazzella[SUP] 7 [/SUP], Yama F Mujadidi[SUP] 4 [/SUP], Lucia Parolini[SUP] 1 [/SUP], Claire Petersen[SUP] 9 [/SUP], Emma Plested[SUP] 4 [/SUP], Katrina Pollock[SUP] 5 [/SUP], Thurkka Rajeswaran[SUP] 7 [/SUP], Maheshi N Ramasamy[SUP] 4 [/SUP], Sarah Rhead[SUP] 4 [/SUP], Hannah Robinson[SUP] 4 [/SUP], Nicola Robinson[SUP] 1 [/SUP], Helen Sanders[SUP] 2 [/SUP], Sonia Serrano Fandos[SUP] 6 [/SUP], Tom Tipton[SUP] 8 [/SUP], Anele Waters[SUP] 7 [/SUP], Panagiota Zacharopoulou[SUP] 1 [/SUP], Eleanor Barnes[SUP] 1 [/SUP], Susanna Dunachie[SUP] 1 [/SUP], Philip Goulder[SUP] 1 [/SUP], Paul Klenerman[SUP] 1 [/SUP], Gavin R Screaton[SUP] 8 [/SUP], Alan Winston[SUP] 3 [/SUP], Adrian Vs Hill[SUP] 2 [/SUP], Sarah C Gilbert[SUP] 2 [/SUP], Miles Carroll[SUP] 8 [/SUP], Andrew J Pollard[SUP] 4 [/SUP], Sarah Fidler[SUP] 3 [/SUP], Julie Fox[SUP] 6 [/SUP], Teresa Lambe[SUP] 2 [/SUP], John Frater[SUP] 1 [/SUP]
Affiliations
- PMID: 35192543
- DOI: 10.1172/jci.insight.157031
Abstract
Duration of protection from SARS-CoV-2 infection in people with HIV (PWH) following vaccination is unclear. In a sub-study of the phase 2/3 the COV002 trial (NCT04400838), 54 HIV positive male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells >350 cells/ul) received two doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and MesoScale Discovery (MSD)), neutralisation, ACE-2 inhibition, gamma interferon ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that 6 months after vaccination the majority of measurable immune responses were greater than pre-vaccination baseline, but with evidence of a decline in both humoral and cell mediated immunity. There was, however, no significant difference compared to a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although were lower than wild type. Pre-existing cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater post-vaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the on-going policy to vaccinate PWH against SARS-CoV-2, and underpin the need for long-term monitoring of responses after vaccination.
Keywords: AIDS/HIV; Adaptive immunity; COVID-19; Cellular immune response; T cells.